Vilanterol
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Vilanterol |
| DrugBank ID | DB09082 |
| Brand Names (EU) | Vilanterol |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 100.00% |
Approved Indication (EMA)
Asthma indication: Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists. patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist. COPD indication: Relvar Ellipta is indica
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bronchitis | 100.00% | DL |
| 2 | obstructive lung disease | 99.97% | DL |
| 3 | chronic obstructive pulmonary disease | 99.76% | DL |
| 4 | hyperlucent lung | 99.72% | DL |
| 5 | compensatory emphysema | 99.72% | DL |
| 6 | interstitial emphysema | 99.72% | DL |
| 7 | tracheal stenosis | 99.68% | DL |
| 8 | bronchial neoplasm (disease) | 99.63% | DL |
| 9 | congenital lobar emphysema | 99.58% | DL |
| 10 | respiratory malformation | 99.52% | DL |
| 11 | tracheal calcification | 99.47% | DL |
| 12 | pulmonary emphysema | 99.47% | DL |
| 13 | laryngotracheitis | 99.37% | DL |
| 14 | Rienhoff syndrome | 99.35% | DL |
| 15 | susceptibility to respiratory infections associated with CD8alpha chain mutation | 99.29% | DL |
| 16 | COPD, severe early onset | 99.25% | DL |
| 17 | allergic asthma | 96.77% | DL |
| 18 | intrinsic asthma | 96.61% | DL |
| 19 | Laubry-Pezzi syndrome | 95.66% | DL |
| 20 | tracheal disease | 95.62% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.